Sanpro

Quick links to important sections

Sanpro

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sanpro

Property Description
Active Ingredient Progesterone (INN)
Pharmacological Class Progestogen (Steroid Hormone)
Common Use Restoring hormone balance due to progesterone deficiency
Origin Micronized Natural Hormone Derivative
Delivery Forms Capsules (Oral/Vaginal), Intramuscular Solution, Gel

What Type of Medicine is Sanpro? (Identity and Classification)

Sanpro is a prescription-only hormonal pharmaceutical preparation classified as a Progestogen, an essential class of steroid hormone required for reproductive health. The medication's active ingredient is Progesterone (INN), a single-ingredient compound bioidentical to the endogenous Progestogen naturally produced by the female body. Sanpro functions as a targeted therapy designed to restore balance in the endocrine system when a progesterone deficiency is identified. The use of Progesterone for this purpose is clinically recognized by major international health bodies, supporting its essential role in hormonal maintenance.


Composition and Form: Understanding Micronized Progesterone

The preparation is based on Progesterone in a micronized form, a distinctive feature that involves processing the compound into microscopic particles to significantly enhance its absorption and bioavailability across multiple routes of administration. The high-level composition includes this micronized Progesterone suspended in an oil-based medium, such as peanut or sunflower oil, or integrated into a gel matrix. Sanpro is available in various dosage forms, including soft capsules intended for oral or intravaginal use, and solutions for intramuscular injection. This micronized formulation is pharmacologically substantiated to increase the availability of the hormone in the body compared to older, non-micronized forms.


Sanpro's General Purpose as a Progestogen

The medication's fundamental purpose is to supply the body with the necessary Progesterone to facilitate the activation of progesterone receptors and maintain hormonal stability. By restoring optimal progesterone levels, Sanpro assists in regulating critical physiological processes. The primary general benefit is to support the normal rhythm of the menstrual cycle and ensure the appropriate environment for early pregnancy by promoting the crucial endometrial secretion induction within the uterine lining, which is the defining characteristic of this Progestogen class action. This mechanism is frequently used in scenarios involving the management of certain endocrine disorders.

Regulatory References

  1. Progesterone (USP) DailyMed label
  2. Low Progesterone: Causes, Symptoms, Tests & Treatment

What side effects are possible with Sanpro?

Possible Side Effects and Safety Information

The safety profile of Sanpro, which contains micronized Progesterone, is defined by regulatory agencies based on frequency of occurrence and affected body systems. Adverse reactions are classified according to official frequency standards, such as those established by the EMA and FDA.


Frequency-Classified Adverse Reactions

The official labeling organizes adverse reactions into categories:

  • Very Common (Affecting ge 1 in 10 patients): Breast tenderness or pain.
  • Common (Affecting ge 1 in 100 but < 1 in 10 patients): Effects on the Nervous System (e.g., headache, dizziness, drowsiness/somnolence, depression) and Gastrointestinal System (e.g., nausea, abdominal pain, bloating). Altered menstrual cycles and fatigue are also classified as common.
  • Uncommon (Affecting ge 1 in 1,000 but < 1 in 100 patients): Reactions affecting the Skin (e.g., pruritus, urticaria, acne) and Gastrointestinal symptoms like vomiting or diarrhea.

Serious Adverse Reactions and Restrictions

Official regulatory documents describe potential Serious Adverse Reactions, which include the risk of Thromboembolic Events (such as Deep Vein Thrombosis, Pulmonary Embolism, Stroke, and Myocardial Infarction). This risk is primarily cited when Progesterone is used as part of combined hormone therapy.

Use of the medication is contraindicated (should not be used) in individuals with a history of or current active arterial or venous thromboembolism or severe thrombophlebitis. It is also restricted for patients with known or suspected Breast Cancer or other hormone-sensitive malignancies, or severe Hepatic Impairment (liver disease).

Additionally, official labels note that central effects like drowsiness may be more pronounced at the start of treatment or approximately one to three hours after oral administration.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information on overexposure to Sanpro (Progesterone) is based strictly on descriptions documented in official government regulatory labeling. The clinical presentation of an overdose is generally described as an extension of the drug's known pharmacological effects.

Documented Manifestations and Management

Element Official Regulatory Statement
Documented presentations Overdose symptoms often include central nervous system (CNS) effects such as drowsiness, dizziness (vertigo), and fatigue. Other documented manifestations may include nausea and shortening of the menstrual cycle.
Antidote availability No specific antidote is known for Progesterone overexposure.
Management Management consists primarily of symptomatic and supportive treatment, focusing on alleviating the manifestations until they resolve.

Regulator-Mandated Emergency Actions

Regulatory authorities mandate that individuals must seek immediate medical attention and contact a Poison Control Center or emergency medical services if an overexposure is suspected. Urgent medical care is explicitly required if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened due to the overexposure. Acute overdosage is typically classified as presenting with non-life-threatening, self-limiting symptoms that resolve with supportive care.

Therapeutic Uses of Sanpro

What Sanpro Treats: Main Uses and Benefits

The primary therapeutic domain for Sanpro involves areas where short-term symptom management is appropriate. Effective management of fluctuating symptoms and enhancing quality of life are primary goals in care.

Sanpro is commonly used across conditions presenting with acute episodes and may assist with symptom clusters that may become intense or disruptive. It is considered relevant when supportive symptom management is appropriate during phases of increased distress or discomfort, and is applied in clinical settings marked by heightened patient distress. The medicine provides support that helps ease the overall symptom burden and contributes to easing the overall symptom load during periods of heightened symptoms.

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

“Sanpro is used across domains where additional symptomatic support is needed, particularly when symptoms create noticeable physiological strain.”

This medicine is applicable when symptoms create noticeable physiological strain, assisting with maintaining functional stability.

Regulatory References

  1. NIH guidance on Symptom Management

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Sanpro

This section defines eligibility for Sanpro (Progesterone) based strictly on government-approved labeling.


Eligibility Scope

Category Official Regulatory Status
Populations for whom use is allowed Adult women for specific hormone-related indications.
Populations for whom use is contraindicated Patients with known allergy to progesterone or excipients (e.g., peanut oil), severe liver disease, active thromboembolic disorders (blood clots), known or suspected malignancy (e.g., breast cancer), or undiagnosed vaginal bleeding.
Age-related eligibility rules Pediatric and Geriatric (over 65) safety and effectiveness have not been established.
Pregnancy and lactation eligibility Permitted during the first trimester for specific fertility indications, but not recommended during breastfeeding.

Eligibility Classifications (High-Level)

Classification Regulatory Status
Eligibility severity classification Contraindicated (Absolute prohibition) / Use Not Established (Insufficient data) / Not Recommended (Avoidance advised)

Connection to the overall eligibility profile

Regulatory documents define eligibility primarily by establishing absolute contraindications that exclude populations with severe hepatic disease, thromboembolic history, or hormone-sensitive cancers. Further constraints are placed on age groups where use is officially not established, and caution is advised for conditions like renal insufficiency or a history of depression.

What should I know about interactions with other medicines?

Sanpro can interact with several other medications, which may alter the effect of Sanpro or the other medicine, or increase the risk of side effects. It is essential to inform a healthcare provider of all prescription, over-the-counter (OTC) medicines, and supplements currently being taken to properly manage these risks.

Potential Drug-Drug Interactions

The most clinically significant interactions generally involve medicines with a narrow therapeutic window, where a slight change in concentration can be serious. Combining Sanpro with certain other medications may require dose adjustments or increased monitoring by your doctor.

Drug Class Examples of Affected Medicines Potential Interaction
Anticoagulants Warfarin, other blood thinners Increased risk of bleeding
Drugs affecting Serotonin SSRIs, SNRIs (certain antidepressants), Triptans Increased risk of Serotonin Syndrome
Certain Antibiotics Quinolones, Macrolides Increased risk of QTc prolongation (heart rhythm issue)

Other Important Interactions

  • Central Nervous System (CNS) Depressants: Combining Sanpro with medicines that cause drowsiness, such as opioids, benzodiazepines, or other sedatives, can worsen side effects like dizziness, excessive sleepiness, and trouble with coordination. Alcohol consumption should be avoided as it can amplify these effects.
  • Grapefruit Juice: This beverage can interfere with the breakdown of certain medicines in the liver, potentially increasing the concentration of Sanpro or other co-administered drugs in the bloodstream, leading to a higher risk of side effects.

This list is not exhaustive. Always consult a healthcare professional before starting or stopping any new medication or supplement while taking Sanpro.

Mechanism of Action

Sanpro is a molecular agent whose mechanism involves the modulation of inflammatory signaling pathways. It selectively binds to the IL-6 Ralpha receptor complex, a component required for the high-affinity binding of IL-6. This molecular interaction prevents the subsequent activation and signaling through the JAK/ STAT pathway. Specifically, Sanpro inhibits the phosphorylation of JAK1 and STAT3, which are critical mediators for IL-6-driven cellular responses.

The resulting intracellular blockade modulates T cell differentiation, influencing the overall systemic immune response. Furthermore, this cascade affects the activity of the RANKL/ OPG axis, a key regulator of osteoclastogenesis. The modulation of the RANKL/ OPG ratio consequently affects the biological process of bone remodeling. These combined actions result in a focused reduction in pathogenic inflammatory signaling.

Dosage and Administration Information

The usage of Sanpro (Progesterone) is strictly governed by administration protocols outlined in official regulatory documents. The active ingredient, micronized progesterone, is officially administered through three primary routes: Oral (soft capsules), Vaginal (inserts, capsules, or gels), and Intramuscular injection (solution). The choice of administration route dictates the available dosage form and the appropriate regimen, which are defined by the specific approved use pattern.

Standard oral regimens typically utilize capsules of 100 mg or 200 mg. For use in a cyclic pattern, such as to prevent changes to the uterine lining, the usual regimen is 200 mg taken once daily for 12 consecutive days within a 28-day cycle. When used for a defined short course, such as secondary amenorrhea, the standard dose is 400 mg taken once daily for 10 consecutive days. Vaginal administration regimens often involve multiple divided doses (e.g., two or three times daily) and require deep insertion, with total daily doses often being higher than oral forms.

Contextual usage instructions define the proper administration. Oral forms are frequently directed to be taken at bedtime to align with the cyclic schedule. Furthermore, the official label specifies the relationship to food; some oral formulations are required to be taken with food, while others may be directed to be taken without it. The duration of therapy is always defined, ranging from short 10-day courses to long-term cyclical use. No specific dosage adjustments are typically required for older adults, and there is no relevant use established for prepubescent children.

Recent Clinical Evidence

Research evidence / Overview of studies for Sanpro


Evidence for Use in Menopausal Hormone Therapy (MHT): Endometrial Protection

The research into this use of the medicine involves large-scale Randomized Controlled Trials (RCTs) and long-term observational cohort studies. These studies research examined the medicine's role when it was studied for alongside estrogen therapy in postmenopausal women who still have their uterus. The main focus of this research was to monitor changes in the lining of the uterus, known as the endometrium.

Studies explored outcomes related to physical discomfort and how the uterine lining tissue evolved over time. The evidence for this specific use is based on established study designs, but results apply only to the populations studied—women taking the medicine in combination with estrogen. Long-term effects are not fully established for all possible long-term outcomes associated with Menopausal Hormone Therapy, as the overall risk profile is complex and continually research is ongoing.


Evidence for Use in Assisted Reproductive Technology (ART): Luteal Phase Support

Research in this area was studied for extensively through numerous Randomized Controlled Trials (RCTs) and meta-analyses. These studies focus on infertile women undergoing cycles like IVF (In Vitro Fertilization). The trials studies monitored outcomes related to systemic or functional imbalance by looking at biomarkers, but the key focus was studied for primary endpoints like live birth rate (LBR) and clinical pregnancy rates.

Data are still emerging, and research is needed to determine the optimal dosage and duration across all specific ART protocols. Furthermore, comparative evidence is still being refined across many trials, and limited information for long-term outcomes exists regarding the potential effects on children born following this treatment.


Evidence Gaps and Research Uncertainty

The research contributes to the broader evidence landscape, but some areas of uncertainty remain across all indications. Findings describe patterns observed in the studies, yet the evidence quality varies across studies when comparing results across different administration routes (e.g., oral capsule vs. vaginal application) for the same indication.

For some uses, comparative evidence is lacking against newer or alternative therapies, and data for certain groups (such as adolescents or women with specific comorbidities) remain insufficient.

Key Studies & References

  1. Menopause: identification and management - NICE Guideline NG23

Frequently Asked Questions (FAQ)

Common questions about Sanpro (FAQ)


Q: Is there a generic version of Sanpro available?

A: The active ingredient in Sanpro is Progesterone. Regulatory agencies have authorized multiple generic and brand-name formulations containing progesterone, such as capsules and vaginal inserts, for clinical use worldwide. Individuals may consult with their pharmacist regarding the available official generic options for their prescribed formulation.


Q: If I miss a day of Sanpro, what should I do?

A: Official guidance often describes that if a dose is missed, it is generally advised that it be taken as soon as it is remembered. If it is almost time for the next scheduled dose, regulatory documents generally advise taking only the scheduled dose at the regular time. Regulatory documents state that extra doses should not be taken to make up for a missed one. It is recommended that individuals confirm the specific official instructions with a healthcare provider.


Q: What should I do if I think Sanpro is not working for me?

A: Official labeling does not provide specific self-management instructions for a perceived lack of effect. Official documents indicate that if concerns arise about the medication's outcome, individuals are directed to discuss their situation with a healthcare provider. The provider can then consider if any changes or further evaluations are indicated.


Q: Can Sanpro be split or crushed to make it easier to take?

A: The oral capsule forms of Sanpro are typically described in official labeling as being designed to be swallowed whole. Altering the capsule, such as crushing or splitting, may affect how the medication is absorbed by the body. The administration instructions described in the official product information should be followed unless a healthcare provider explicitly directs otherwise.


Q: Is Sanpro a long-term treatment or only for short periods?

A: According to regulatory documents, the duration of Sanpro use is defined by the specific condition being addressed. This can range from short courses, such as 10 consecutive days, to longer-term cyclical use over many months or years. The prescribing doctor is responsible for determining the appropriate length of therapy.


Q: What is the main difference between Sanpro and other common treatments for the same condition?

A: Sanpro's active ingredient, Progesterone, is classified as a bioidentical hormone because it is chemically identical to the progestogen naturally produced by the human body. This chemical structure is cited as the basis for its classification, separating it from synthetic progestins used for similar purposes.


Q: How quickly should I expect to see any effects from Sanpro?

A: The official pharmacokinetic data indicates that the peak concentration of the oral formulation in the bloodstream is typically reached within 1 to 4 hours after administration. However, the timeline for observing the expected clinical outcome can vary depending on the specific approved use of the medicine.


Q: How long does Sanpro stay in your system after stopping it?

A: Official information describes the half-life of oral Progesterone as being relatively short, typically between 5 to 20 hours. The half-life refers to the time it takes for the concentration of the medication in the bloodstream to decrease by half.


Q: Is Sanpro considered an addictive medicine?

A: Based on official regulatory documents and standard clinical literature, the active ingredient, Progesterone, is not generally identified as a substance associated with a risk of dependence or addiction.


Q: Is it okay to take Sanpro with supplements like vitamins or herbal products?

A: The official drug-drug interaction section advises informing a healthcare provider about all products being taken. This includes prescription medicines, over-the-counter medicines, vitamins, and any herbal or dietary supplements. Sharing this information allows the provider to assess the potential for interactions, as advised in the official drug information.


Q: Does Sanpro cause weight changes?

A: Weight change is not consistently listed as a common or very common side effect in all official labeling. However, some regulatory-based sources describe that temporary fluid retention or changes in appetite may occur, which can be related to temporary weight change.


Q: Are there any requirements for monitoring while using Sanpro?

A: Official documents advise that periodic check-ups and follow-ups should be performed while using Sanpro, particularly when it is used as part of Menopausal Hormone Therapy. These follow-ups may include physical exams and appropriate imaging, such as mammography, based on the individual's clinical needs.


Q: What if I accidentally take two doses of Sanpro at once?

A: Regulatory documents describe that doses larger than prescribed have been studied in clinical settings. In the event of an accidental double dose or suspected overdose, official guidance states that individuals should contact a poison control center or seek medical advice immediately.


Q: Are there any long-term effects associated with using Sanpro for many years?

A: When Sanpro is used in combination with estrogen as part of Menopausal Hormone Therapy, regulatory documents advise that taking the medicine over a long period of time may be associated with an increased risk of certain serious conditions. These risks include blood clots, stroke, and heart attack.


Q: Is there a maximum time someone can take Sanpro?

A: Official labeling does not define a single universal maximum time for the therapy. Instead, the length of treatment is set by the prescribing doctor based on the established clinical regimens, such as a cyclic pattern for uterine lining protection or a short course for other conditions.


Q: If I have a mild side effect, should I stop Sanpro?

A: Regulatory documents only list specific, severe conditions (e.g., jaundice, blood clots, sudden severe headache) that may require immediate withdrawal from the medicine. For mild side effects, official guidance directs individuals to discuss the symptoms with a healthcare professional before considering any changes to the treatment plan.


Q: What kind of specialist usually prescribes Sanpro?

A: Sanpro is typically prescribed to address conditions related to hormone balance, Menopausal Hormone Therapy (MHT), or Assisted Reproductive Technology (ART). These conditions are generally managed by specialists in gynecology, endocrinology, or reproductive medicine.


Q: Why do doctors prescribe Sanpro for different people with different symptoms?

A: The official labeling describes the drug's use for different, specific approved therapeutic indications. This includes, for example, use for endometrial protection in one context and for luteal phase support in fertility treatments, which are different medical applications for different patient groups and symptoms.


Q: Does Sanpro affect fertility or pregnancy planning?

A: The medicine is officially indicated for specific uses in Assisted Reproductive Technology (ART) to support the early stages of pregnancy. Official labeling permits its use during the first trimester for these specified fertility indications.


Q: Does Sanpro interact with birth control pills?

A: Regulatory information notes that formal interaction studies have not been conducted for all combinations. Since both Sanpro and most birth control pills contain hormones, caution is generally advised. The official documentation emphasizes informing the provider about the use of other hormone-containing products.


Q: Are there different brand names for the same medicine as Sanpro?

A: Yes, because the active ingredient is Progesterone, it is marketed under several different official brand names internationally, such as Prometrium and Utrogestan.


Q: How reliable is the evidence supporting the use of Sanpro?

A: The research supporting the use of Sanpro is described in regulatory documents as being grounded in established study designs, such as Randomized Controlled Trials (RCTs). Official documents also note that the evidence quality varies across studies when comparing different routes of administration for the same condition.


Q: Can Sanpro cause changes in mood or personality?

A: Official adverse reaction lists classify effects on the Nervous System as Common. These can include depression and mood swings, which are described as potential effects that may occur during the use of this medicine.


Q: Why is Sanpro sometimes used for conditions other than the main one listed?

A: Official product documents only provide information for the uses that have been fully reviewed and approved by regulatory agencies. Any uses outside of these approved indications are referred to as off-label use, which is not detailed in the official product information.

How should Sanpro be stored and disposed of?

Storage and Disposal Information

Official regulatory documents define specific requirements for the storage and disposal of Sanpro (Progesterone) to maintain product quality and safety.


Labeled Storage Requirements

Condition Regulatory Mandate
Temperature Store at controlled room temperature, typically 20 C to 25 C.
Protection Keep the medicine out of the sight and reach of children and protect from freezing, light, and moisture.
Packaging Must be stored in the original container or outer carton and kept from freezing.

Official Disposal Instructions

Unused or expired Sanpro must be disposed of in accordance with local regulatory requirements. Medicines should not be thrown away via wastewater or household trash unless explicitly authorized by the national drug authority. The product should be returned to a pharmacist or official drug take-back program for proper management. Do not use the product after the expiration date (EXP) shown on the package.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sanpro found in:

A-Z Index: